These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 18971540

  • 41. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells.
    Shinomiya K, Mizushige K, Fukunaga M, Masugata H, Ohmori K, Kohno M, Senda S.
    J Int Med Res; 2004; 32(2):170-5. PubMed ID: 15080021
    [Abstract] [Full Text] [Related]

  • 42. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
    Sada T, Saito H.
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008
    [Abstract] [Full Text] [Related]

  • 43. Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms.
    Yokokura H, Hiromatsu S, Akashi H, Kato S, Aoyagi S.
    Surg Today; 2007 Dec; 37(6):468-73. PubMed ID: 17522763
    [Abstract] [Full Text] [Related]

  • 44. Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
    Tada T, Nawata J, Wang H, Onoue N, Zhulanqiqige D, Ito K, Sugimura K, Fukumoto Y, Shimokawa H.
    Cardiovasc Res; 2008 Dec 01; 80(3):346-53. PubMed ID: 18687705
    [Abstract] [Full Text] [Related]

  • 45. Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.
    Nakamura T, Saito Y, Saito T, Kurabayashi M.
    J Pharmacol Sci; 2006 Oct 01; 102(2):239-42. PubMed ID: 17031066
    [Abstract] [Full Text] [Related]

  • 46. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
    Yamamoto E, Lai ZF, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Ito T, Ogawa H, Kim-Mitsuyama S.
    J Hypertens; 2006 Oct 01; 24(10):2057-69. PubMed ID: 16957567
    [Abstract] [Full Text] [Related]

  • 47. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
    Suzuki H, Inoue T, Kobayashi K, Shoda J, Nakamoto H.
    Adv Perit Dial; 2006 Oct 01; 22():18-23. PubMed ID: 16983932
    [Abstract] [Full Text] [Related]

  • 48. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
    Ohmura C, Watada H, Shimizu T, Sakai K, Uchino H, Fujitani Y, Kanazawa A, Hirose T, Kawamori R.
    Endocr J; 2007 Dec 01; 54(5):805-11. PubMed ID: 17895576
    [Abstract] [Full Text] [Related]

  • 49. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
    Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, Fujisawa Y, Lu XM, Fu H, Du J, Ohmori K, Hosomi N, Kimura S, Kiyomoto H, Nishiyama A.
    J Hypertens; 2009 Sep 01; 27(9):1855-62. PubMed ID: 19633569
    [Abstract] [Full Text] [Related]

  • 50. Evaluation of adriamycin nephropathy by an in vivo electron paramagnetic resonance.
    Oteki T, Nagase S, Yokoyama H, Ohya H, Akatsuka T, Tada M, Ueda A, Hirayama A, Koyama A.
    Biochem Biophys Res Commun; 2005 Jul 01; 332(2):326-31. PubMed ID: 15910741
    [Abstract] [Full Text] [Related]

  • 51. In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker.
    Sonta T, Inoguchi T, Matsumoto S, Yasukawa K, Inuo M, Tsubouchi H, Sonoda N, Kobayashi K, Utsumi H, Nawata H.
    Biochem Biophys Res Commun; 2005 May 06; 330(2):415-22. PubMed ID: 15796899
    [Abstract] [Full Text] [Related]

  • 52. Azelnidipine.
    Wellington K, Scott LJ.
    Drugs; 2003 May 06; 63(23):2613-21; discussion 2623-4. PubMed ID: 14636080
    [Abstract] [Full Text] [Related]

  • 53. Acute effects of intravenous nifedipine or azelnidipine on open-loop baroreflex static characteristics in rats.
    Yamamoto H, Kawada T, Shimizu S, Kamiya A, Turner MJ, Miyazaki S, Sugimachi M.
    Life Sci; 2015 Apr 01; 126():37-41. PubMed ID: 25707754
    [Abstract] [Full Text] [Related]

  • 54. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study.
    Watanabe M, Hirano T, Okamoto S, Shiraishi S, Tomiguchi S, Uchino M.
    Hypertens Res; 2010 Jan 01; 33(1):43-8. PubMed ID: 19876061
    [Abstract] [Full Text] [Related]

  • 55. Tilting-induced decrease in systolic blood pressure in bedridden hypertensive elderly inpatients: effects of azelnidipine.
    Morimoto S, Takahashi T, Okaishi K, Nakahashi T, Nomura K, Kanda T, Okuro M, Murai H, Nishino T, Matsumoto M.
    Hypertens Res; 2006 Dec 01; 29(12):943-9. PubMed ID: 17378366
    [Abstract] [Full Text] [Related]

  • 56. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
    Miyazaki S, Hamada T, Hirata S, Ohtahara A, Mizuta E, Yamamoto Y, Kuwabara M, Nosaka Y, Igawa O, Ogino K, Kato M, Yoshida A, Ninomiya H, Cheng J, Moriwaki Y, Yamamoto K, Hisatome I.
    Clin Exp Hypertens; 2014 Dec 01; 36(7):447-53. PubMed ID: 24433018
    [Abstract] [Full Text] [Related]

  • 57. Renoprotective effect of azelnidipine in rats.
    Kurashige T, Abe K, Furusu A, Miyazaki M, Obata Y, Xia Z, Nakazawa M, Nakazawa Y, Funakoshi S, Harada T, Koji T, Kohno S.
    Biol Pharm Bull; 2008 Dec 01; 31(12):2237-44. PubMed ID: 19043206
    [Abstract] [Full Text] [Related]

  • 58. Spectroscopic studies on the interaction of azelnidipine with bovine serum albumin.
    Wang N, Ye L, Yan F, Xu R.
    Int J Pharm; 2008 Mar 03; 351(1-2):55-60. PubMed ID: 18029121
    [Abstract] [Full Text] [Related]

  • 59. Noninvasive mapping of the redox status in septic mouse by in vivo electron paramagnetic resonance imaging.
    Fujii HG, Sato-Akaba H, Emoto MC, Itoh K, Ishihara Y, Hirata H.
    Magn Reson Imaging; 2013 Jan 03; 31(1):130-8. PubMed ID: 22902472
    [Abstract] [Full Text] [Related]

  • 60. Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.
    Koyama Y, Takeishi Y, Takahashi H, Shishido T, Arimoto T, Niizeki T, Harada M, Suzuki S, Kitahara T, Sasaki T, Kubota I.
    Cardiovasc Drugs Ther; 2007 Feb 03; 21(1):69-72. PubMed ID: 17318380
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.